ClinicalTrials.gg
CompletedNCT03684044Updated Jan 6, 2021Results posted

Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza

A Phase 3 interventional study of Baloxavir Marboxil and Placebo in Influenza, sponsored by Hoffmann-La Roche. Completed at 170 sites in 28 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-01-06.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
363
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing baloxavir in Influenza, Human — 7 open to participants now, 7 under way, 5 of them phase 3. baloxavir · Influenza, Human.

Enrollment
12th of 18
363 · median 483
Started
2019
with 3 others
Phase 3
12 of 18
5 open now
Registered
6th of 18
by date
Lead sponsor
7 of 18
Hoffmann-La Roche

Among the 18 studies testing baloxavir in Influenza, Human, this one is the 12th largest by enrollment, is one of 4 that started in 2019, is one of 12 in phase 3, and was the 6th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

7 of the 18 studies testing baloxavir in Influenza, Human are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About baloxavir

baloxavir: first FDA approval 2018 (XOFLUZA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing baloxavir in Influenza, Human, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety, and pharmacokinetics of baloxavir marboxil in combination with a standard-of-care (SOC) neuraminidase inhibitor (NAI) (i.e., oseltamivir, zanamivir, or peramivir) compared with a matching placebo in combination with a SOC NAI in hospitalized patients with influenza.

03

Conditions studied

  • Influenza

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants: Signed by any participant capable of giving consent, or, where the participant is not capable of giving consent, by his or her legal/authorized representative
  • Adolescent participants not able to legally consent: written informed consent for study participation is obtained from participant's parents or legal guardian, with assent as appropriate by the participant, depending on the participant's level of understanding and capability to provide assent
  • Participants who require hospitalization for severe influenza or acquire influenza during hospitalization, the severity of which requires an extension of hospitalization
  • Diagnosis of influenza A and/or B by a positive Rapid Influenza Diagnostic Test (RIDT) or reverse transcriptase-polymerase chain reaction (RT-PCR)
  • The time interval between the onset of symptoms and randomization is within 96 hours
  • A score of ≥4 based on the National Early Warning Score 2 (NEWS2)
  • Participants will require objective criteria of seriousness defined by at least one of the following criteria:
  • Requires ventilation or supplemental oxygen to support respiration
  • Has a complication related to influenza that requires hospitalization (e.g., pneumonia, central nervous system involvement, myositis, rhabdomyolysis, acute exacerbation of chronic kidney disease, asthma or (COPD), severe dehydration, myocarditis, pericarditis, exacerbation of ischemic heart disease)
  • For women of : Agreement to remain abstinent or use methods with a failure rate of \< 1% per year during the treatment period and for 28 days after the last dose of study treatment. Hormonal contraceptive methods must be supplemented by a barrier method.

Exclusion criteria

Exclusion Criteria:

  • Participants who have received more than 48 hours of antiviral treatment for the current influenza infection prior to screening
  • Participants who have received baloxavir marboxil for the current influenza infection
  • Known to neuraminidase inhibitors
  • Participants hospitalized for exclusively social reasons (e.g., lack of caregivers at home)
  • Participants expected to die or be discharged within 48 hours, according to the investigator's judgement
  • Participants weighing \< 40 kg
  • Participants with known severe renal impairment (estimated \< 30 mL/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis
  • Participants with any of the following laboratory abnormalities detected within 24 hours prior to or during screening (according to local laboratory reference ranges:
  • (ALT) or Aspartate Transaminase (AST) level > 5 times the (ULN) OR
  • ALT or AST > 3 times the ULN and total level > 2 times the ULN
  • Pregnant or breastfeeding, or positive pregnancy test in a predose examination, or intending to become pregnant during the study or within 28 days after the last dose of study treatment
  • Exposure to an drug within 5 half-lives or 30 days (whichever is longer) of randomization
  • Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study
  • Known to baloxavir marboxil or the drug product
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
363 participants (actual)

Study arms

  • Experimental
    Baloxavir Marboxil

    Participants will receive at least two doses of baloxavir marboxil on Days 1 and 4. A third dose of Baloxavir will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5. Study treatment will be given in combination with SOC NAI (i.e., oseltamivir, zanamivir, or peramivir) in accordance with local clinical practice.

    Drug: Baloxavir Marboxil

  • Placebo comparator
    Placebo

    Participants will receive at least two doses of placebo on Day 1 and 4. A third dose of placebo will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5. Study treatment will be given in combination with SOC NAI (i.e., oseltamivir, zanamivir, or peramivir) in accordance with local clinical practice.

    Other: Placebo

Interventions

  • Baloxavir marboxil will be administered as a weight-based dose on Days 1 and 4. A third dose will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.

  • OtherPlacebo

    Participants will receive matching placebo on Days 1, 4 and 7.

06

What researchers measure

Primary outcomes

  1. Time to Clinical Improvement

    Time to Clinical Improvement (TTCI) is defined as Time to Hospital Discharge OR Time to NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours.

    Time frame: Up to Day 35

Secondary outcomes

  1. Response Rates of the 6-Point Ordinal Scale at Day 7

    The ordinal scale categories are: Category 1) Discharged (or "ready for discharge") Category 2) Non-ICU hospital ward (or "ready for hospital ward") not requiring supplemental oxygen/non-invasive ventilation Category 3) Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen/non-invasive ventilation Category 4) ICU without mechanical (invasive) ventilation (or "ready for ICU admission") Category 5) Mechanical (invasive) ventilation Category 6) Death

    Time frame: Day 7

  2. Time to Clinical Response

    Time to Clinical Response is based on temperature ranges, oxygen saturation, respiratory status, heart rate, and hospitalization status.

    Time frame: Up to Day 35

  3. Percentage of Participants on Mechanical Ventilation

    Time frame: Up to Day 35

  4. Duration of Mechanical Ventilation

    Time frame: Up to Day 35

  5. Percentage of Participants Requiring ICU Stay

    Time frame: Up to Day 35

  6. Duration of ICU Stay

    Time frame: Up to Day 35

  7. Time to Clinical Failure

    Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission, corresponding to ordinal scale categories 6, 5, and 4, respectively, from baseline

    Time frame: Up to Day 35

  8. Time to Hospital Discharge

    Time frame: Up to Day 35

  9. Percentage of Participants With Post-Treatment Influenza-Related Complications

    Influenza-related complications included pneumonia, myositis or rhabdomyolysis, encephalitis or encephalopathy, myocarditis and/or pericarditis, otitis media, sinusitis, exacerbation of COPD/asthma, sepsis, acute lung injury or acute respiratory distress syndrome.

    Time frame: Up to Day 35

  10. Mortality Rate at Day 7

    Time frame: Up to Day 7

  11. Mortality Rate at Day 28

    Time frame: Up to Day 28

  12. Time to NEWS2 of ≤ 2 Maintained for 24 Hours

    A score of 0 (Range 0 - 3) indicates normal health conditions.

    Time frame: Up to Day 35

  13. Time to Cessation of Viral Shedding by Virus Titer

    Time to cessation of viral shedding by virus titer is defined as the time, in hours, between the initiation of study treatment and first time when the influenza virus titer is below the limit of detection (0.75 log10 TCID50/mL)

    Time frame: Screening (baseline) and on Days 2, 3, 4, 5, 7, and 10

  14. Change From Baseline in Influenza Virus Titer at Each Timepoint

    Influenza virus titer is the quantity of influenza virus in a given volume within the samples obtained from nasal swabs. If influenza virus titer was less than the lower limit of quantification, the virus titer was imputed as 0.749 (log10TCID50/mL). A lower value indicates lower viral titer.

    Time frame: Days 2, 3, 4, 5, 7, and 10

  15. Percentage of Participants With Positive Influenza Virus Titer at Each Timepoint

    Influenza virus titer is the quantity of influenza virus in a given volume within the samples obtained from nasal swabs. If influenza virus titer was less than the lower limit of quantification, the virus titer was imputed as 0.749 (log10 TCID50/mL). A lower value indicates lower viral titer.

    Time frame: Days 2, 3, 4, 5, 7, and 10

  16. Area Under the Curve in Virus Titer

    Time frame: Days 1, 2, 3, 4, 5, 7, and 10

  17. Time to Cessation of Viral Shedding by RT-PCR

    Time to cessation of viral shedding by RT-PCR, in hours, is defined as the time between the initiation of study treatment and first time when the virus RNA by RT-PCR is below the limit of detection (2.05 for flu A and 2.83 for flu B log10 virus particles/mL)

    Time frame: Screening (baseline) and on Days 2, 3, 4, 5, 7, and 10

  18. Change From Baseline in the Amount of Virus RNA (RT-PCR) at Each Timepoint

    If the amount of virus RNA was less than the lower limit of quantification, the amount of virus RNA was imputed as 2.18 for flu A and 2.93 for flu B (log10 virus particles/mL)

    Time frame: Days 2, 3, 4, 5, 7, and 10

  19. Percentage of Participants Positive by RT-PCR at Each Timepoint

    If the amount of virus RNA was less than the lower limit of quantification, the amount of virus RNA was imputed as 2.18 for flu A and 2.93 for flu B (log10 virus particles/mL)

    Time frame: Days 2, 3, 4, 5, 7, and 10

  20. Area Under the Curve in the Amount of Virus RNA (RT-PCR)

    Time frame: Days 1, 2, 3, 4, 5, 7, and 10

  21. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. A serious adverse event (SAE) is any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability/ incapacity, is a congenital anomaly/ birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above.

    Time frame: Up to Day 35

  22. Percentage of Participants With AEs and SAEs Leading to Discontinuation From Treatment

    Discontinuation from study treatment.

    Time frame: Up to Day 35

  23. Percentage of Participants With Any Post-Treatment ALT and AST Above Baseline and >3 × ULN, >5 × ULN, >10 × ULN

    ALT = alanine aminotransferase AST = aspartate transaminase

    Time frame: Up to Day 35

  24. Plasma Concentration of Baloxavir (Active Metabolite) at Specified Time Points

    Time frame: Day 1, 2, 4, 5, 7 and 8

  25. Area Under the Concentration to Time Curve From Time 0 to 72 Hours (AUC0-72) of Baloxavir

    Time frame: 0, 0.5, 2, 4, 10, 24, 72 hours from dose on Day 1 and on Day 4, and Day 7, Day 8

  26. Maximum Plasma Concentration (Cmax) of Baloxavir

    Time frame: 0, 0.5, 2, 4, 10, 24, 72 hours from dose on Day 1 and on Day 4, and Day 7, Day 8

  27. Apparent Half-Life (T1/2) of Baloxavir

    Time frame: 0, 0.5, 2, 4, 10, 24, 72 hours from dose on Day 1 and on Day 4, and Day 7, Day 8

  28. Concentration at 24 Hours (C24) of Baloxavir

    Time frame: 0, 0.5, 2, 4, 10, 24, 72 hours from dose on Day 1 and on Day 4, and Day 7, Day 8

07

Results

Posted Nov 30, 2020

Participant flow

A total of 363 patients received at least one dose of study treatment and were included in the analyses of safety and efficacy.

Participant flow — Overall Study
MilestoneBaloxavir MarboxilPlacebo
Started239124
Completed217104
Not completed2220
Withdrew: Adverse event30
Withdrew: Death47
Withdrew: Lost to follow-up32
Withdrew: Patient not available02
Withdrew: Physician decision10
Withdrew: Withdrawal by subject119

Outcome measures

PrimaryTime to Clinical Improvement

Time to Clinical Improvement (TTCI) is defined as Time to Hospital Discharge OR Time to NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours.

Time frame:
Up to Day 35
Reported as:
Median · hours
Time to Clinical Improvement
hoursBaloxavir MarboxilPlacebo
Time to Clinical Improvement97.5 (75.9 to 117.2)100.2 (75.9 to 144.4)
Statistical analysis
  • Baloxavir Marboxil vs Placebo · Gehan Wilcoxon · p = 0.4666 · Median difference (net): -2.7 · 95% CI -53.4 to 25.9The Gehan Wilcoxon test was used to analyze the TTCI data because the proportional hazards assumption was violated
SecondaryResponse Rates of the 6-Point Ordinal Scale at Day 7

The ordinal scale categories are: Category 1) Discharged (or "ready for discharge") Category 2) Non-ICU hospital ward (or "ready for hospital ward") not requiring supplemental oxygen/non-invasive ventilation Category 3) Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen/non-invasive ventilation Category 4) ICU without mechanical (invasive) ventilation (or "ready for ICU admission") Category 5) Mechanical (invasive) ventilation Category 6) Death

Time frame:
Day 7
Reported as:
Number · percentage of participants
Response Rates of the 6-Point Ordinal Scale at Day 7
percentage of participantsBaloxavir MarboxilPlacebo
Category 149.245.4
Category 222.624.1
Category 320.122.2
Category 44.01.9
Category 53.54.6
Category 60.51.9
Statistical analysis
  • Baloxavir Marboxil vs Placebo · Cochran-Mantel-Haenszel · p = 0.6326Statistic was stratified by region, NEWS2 at baseline (≤7, \>7), and time from symptom onset to study treatment (≤48 hours, \>48 hours)
SecondaryTime to Clinical Response

Time to Clinical Response is based on temperature ranges, oxygen saturation, respiratory status, heart rate, and hospitalization status.

Time frame:
Up to Day 35
Reported as:
Median · hours
Time to Clinical Response
hoursBaloxavir MarboxilPlacebo
Time to Clinical Response138.3 (120.0 to 161.1)145.1 (128.0 to 187.2)
Statistical analysis
  • Baloxavir Marboxil vs Placebo · Gehan Wilcoxon · p = 0.3272 · Mean difference (net): -6.8 · 95% CI -50.9 to 17.7The Gehan Wilcoxon test was used to analyze the TTCI data because the proportional hazards assumption was violated
SecondaryPercentage of Participants on Mechanical Ventilation
Time frame:
Up to Day 35
Reported as:
Number · percentage of participants
Percentage of Participants on Mechanical Ventilation
percentage of participantsBaloxavir MarboxilPlacebo
Percentage of Participants on Mechanical Ventilation5.36.1
SecondaryDuration of Mechanical Ventilation
Time frame:
Up to Day 35
Reported as:
Median · hours
Duration of Mechanical Ventilation
hoursBaloxavir MarboxilPlacebo
Duration of Mechanical Ventilation150.25 (18.0 to 465.0)91.00 (24.0 to 407.0)
SecondaryPercentage of Participants Requiring ICU Stay
Time frame:
Up to Day 35
Reported as:
Number · percentage of participants
Percentage of Participants Requiring ICU Stay
percentage of participantsBaloxavir MarboxilPlacebo
Percentage of Participants Requiring ICU Stay4.33.5
SecondaryDuration of ICU Stay
Time frame:
Up to Day 35
Reported as:
Median · hours
Duration of ICU Stay
hoursBaloxavir MarboxilPlacebo
Duration of ICU Stay138.55 (23.7 to 362.0)71.78 (18.7 to 139.4)
SecondaryTime to Clinical Failure

Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission, corresponding to ordinal scale categories 6, 5, and 4, respectively, from baseline

Time frame:
Up to Day 35
Reported as:
Median · hours
Time to Clinical Failure
hoursBaloxavir MarboxilPlacebo
Time to Clinical FailureNA (NA to NA)NA (NA to NA)
SecondaryTime to Hospital Discharge
Time frame:
Up to Day 35
Reported as:
Median · hours
Time to Hospital Discharge
hoursBaloxavir MarboxilPlacebo
Time to Hospital Discharge166.7 (144.7 to 190.7)167.3 (146.4 to 211.1)
SecondaryPercentage of Participants With Post-Treatment Influenza-Related Complications

Influenza-related complications included pneumonia, myositis or rhabdomyolysis, encephalitis or encephalopathy, myocarditis and/or pericarditis, otitis media, sinusitis, exacerbation of COPD/asthma, sepsis, acute lung injury or acute respiratory distress syndrome.

Time frame:
Up to Day 35
Reported as:
Number · percentage of participants
Percentage of Participants With Post-Treatment Influenza-Related Complications
percentage of participantsBaloxavir MarboxilPlacebo
Percentage of Participants With Post-Treatment Influenza-Related Complications10.614.0
SecondaryMortality Rate at Day 7
Time frame:
Up to Day 7
Reported as:
Number · percentage of participants
Mortality Rate at Day 7
percentage of participantsBaloxavir MarboxilPlacebo
Mortality Rate at Day 70.5 (0.01 to 2.65)2.6 (0.55 to 7.50)
SecondaryMortality Rate at Day 28
Time frame:
Up to Day 28
Reported as:
Number · percentage of participants
Mortality Rate at Day 28
percentage of participantsBaloxavir MarboxilPlacebo
Mortality Rate at Day 281.9 (0.53 to 4.85)5.3 (1.96 to 11.10)
SecondaryTime to NEWS2 of ≤ 2 Maintained for 24 Hours

A score of 0 (Range 0 - 3) indicates normal health conditions.

Time frame:
Up to Day 35
Reported as:
Median · hours
Time to NEWS2 of ≤ 2 Maintained for 24 Hours
hoursBaloxavir MarboxilPlacebo
Time to NEWS2 of ≤ 2 Maintained for 24 Hours106.3 (88.3 to 138.3)127.2 (77.4 to 156.3)
SecondaryTime to Cessation of Viral Shedding by Virus Titer

Time to cessation of viral shedding by virus titer is defined as the time, in hours, between the initiation of study treatment and first time when the influenza virus titer is below the limit of detection (0.75 log10 TCID50/mL)

Time frame:
Screening (baseline) and on Days 2, 3, 4, 5, 7, and 10
Reported as:
Median · hours
Time to Cessation of Viral Shedding by Virus Titer
hoursBaloxavir MarboxilPlacebo
Time to Cessation of Viral Shedding by Virus Titer23.9 (23.2 to 24.5)63.7 (46.4 to 68.1)
SecondaryChange From Baseline in Influenza Virus Titer at Each Timepoint

Influenza virus titer is the quantity of influenza virus in a given volume within the samples obtained from nasal swabs. If influenza virus titer was less than the lower limit of quantification, the virus titer was imputed as 0.749 (log10TCID50/mL). A lower value indicates lower viral titer.

Time frame:
Days 2, 3, 4, 5, 7, and 10
Reported as:
Number · log10 TCID50/ml
Change From Baseline in Influenza Virus Titer at Each Timepoint
log10 TCID50/mlBaloxavir MarboxilPlacebo
Day 2-2.36-1.00
Day 3-2.70-1.93
Day 4-2.88-2.50
Day 5-3.01-2.81
Day 7-3.00-2.95
Day 10-3.02-3.06
SecondaryPercentage of Participants With Positive Influenza Virus Titer at Each Timepoint

Influenza virus titer is the quantity of influenza virus in a given volume within the samples obtained from nasal swabs. If influenza virus titer was less than the lower limit of quantification, the virus titer was imputed as 0.749 (log10 TCID50/mL). A lower value indicates lower viral titer.

Time frame:
Days 2, 3, 4, 5, 7, and 10
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Influenza Virus Titer at Each Timepoint
percentage of participantsBaloxavir MarboxilPlacebo
Day 237.780.3
Day 318.653.4
Day 47.926.7
Day 51.320.8
Day 72.75.8
Day 101.41.4
SecondaryArea Under the Curve in Virus Titer
Time frame:
Days 1, 2, 3, 4, 5, 7, and 10
Reported as:
Mean · log10 TCID50/mL*hours
Area Under the Curve in Virus Titer
log10 TCID50/mL*hoursBaloxavir MarboxilPlacebo
Area Under the Curve in Virus Titer291.68 ± 176.68332.04 ± 183.63
SecondaryTime to Cessation of Viral Shedding by RT-PCR

Time to cessation of viral shedding by RT-PCR, in hours, is defined as the time between the initiation of study treatment and first time when the virus RNA by RT-PCR is below the limit of detection (2.05 for flu A and 2.83 for flu B log10 virus particles/mL)

Time frame:
Screening (baseline) and on Days 2, 3, 4, 5, 7, and 10
Reported as:
Median · hours
Time to Cessation of Viral Shedding by RT-PCR
hoursBaloxavir MarboxilPlacebo
Time to Cessation of Viral Shedding by RT-PCR216.3 (211.3 to 239.8)261.1 (236.4 to NA)
SecondaryChange From Baseline in the Amount of Virus RNA (RT-PCR) at Each Timepoint

If the amount of virus RNA was less than the lower limit of quantification, the amount of virus RNA was imputed as 2.18 for flu A and 2.93 for flu B (log10 virus particles/mL)

Time frame:
Days 2, 3, 4, 5, 7, and 10
Reported as:
Number · log10 virus particles/mL
Change From Baseline in the Amount of Virus RNA (RT-PCR) at Each Timepoint
log10 virus particles/mLBaloxavir MarboxilPlacebo
Day 2-0.98-0.66
Day 3-1.54-1.19
Day 4-2.35-1.84
Day 5-2.91-2.39
Day 7-3.15-2.96
Day 10-3.69-3.21
SecondaryPercentage of Participants Positive by RT-PCR at Each Timepoint

If the amount of virus RNA was less than the lower limit of quantification, the amount of virus RNA was imputed as 2.18 for flu A and 2.93 for flu B (log10 virus particles/mL)

Time frame:
Days 2, 3, 4, 5, 7, and 10
Reported as:
Number · percentage of participants
Percentage of Participants Positive by RT-PCR at Each Timepoint
percentage of participantsBaloxavir MarboxilPlacebo
Day 295.696.3
Day 390.093.3
Day 488.187.9
Day 579.985.4
Day 769.668.0
Day 1046.750.5
SecondaryArea Under the Curve in the Amount of Virus RNA (RT-PCR)
Time frame:
Days 1, 2, 3, 4, 5, 7, and 10
Reported as:
Mean · log10 virus particles/mL*hours
Area Under the Curve in the Amount of Virus RNA (RT-PCR)
log10 virus particles/mL*hoursBaloxavir MarboxilPlacebo
Area Under the Curve in the Amount of Virus RNA (RT-PCR)676.40 ± 371.72740.15 ± 484.07
SecondaryPercentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. A serious adverse event (SAE) is any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability/ incapacity, is a congenital anomaly/ birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above.

Time frame:
Up to Day 35
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
percentage of participantsBaloxavir MarboxilPlacebo
AEs45.250.0
SAEs12.115.3
SecondaryPercentage of Participants With AEs and SAEs Leading to Discontinuation From Treatment

Discontinuation from study treatment.

Time frame:
Up to Day 35
Reported as:
Number · percentage of participants
Percentage of Participants With AEs and SAEs Leading to Discontinuation From Treatment
percentage of participantsBaloxavir MarboxilPlacebo
AEs1.33.2
SAEs0.81.6
SecondaryPercentage of Participants With Any Post-Treatment ALT and AST Above Baseline and >3 × ULN, >5 × ULN, >10 × ULN

ALT = alanine aminotransferase AST = aspartate transaminase

Time frame:
Up to Day 35
Reported as:
Number · percentage of participants
Percentage of Participants With Any Post-Treatment ALT and AST Above Baseline and >3 × ULN, >5 × ULN, >10 × ULN
percentage of participantsBaloxavir MarboxilPlacebo
AST(U/L) or ALT (U/L) >3 x ULN4.68.9
AST(U/L) or ALT (U/L) >5 x ULN0.83.2
AST(U/L) or ALT (U/L) >10 x ULN01.6
SecondaryPlasma Concentration of Baloxavir (Active Metabolite) at Specified Time Points
Time frame:
Day 1, 2, 4, 5, 7 and 8
Reported as:
Mean · ng/mL
Plasma Concentration of Baloxavir (Active Metabolite) at Specified Time Points
ng/mLBaloxavir Marboxil
Day 1 - 30 minutes postdose37.82 ± 23.61
Day 1 - 2 hours postdose75.06 ± 52.16
Day 1 - 4 hours postdose95.85 ± 58.36
Day 1 - 10 hours postdose64.47 ± 39.47
Day 2 - 24 hours postdose53.36 ± 37.42
Day 4 - Predose24.26 ± 15.87
Day 4 - 30 minutes postdose49.16 ± 52.07
Day 4 - 2 hours postdose109.66 ± 95.22
Day 4 - 4 hours postdose117.69 ± 60.54
Day 4 - 10 hours postdose94.08 ± 49.71
Day 5 - 24 hours postdose77.98 ± 42.89
Day 7 - predose23.31 ± 25.87
Day 8 - 24 hours postdose105.00 ± NA
Visit 828.37 ± 61.61
SecondaryArea Under the Concentration to Time Curve From Time 0 to 72 Hours (AUC0-72) of Baloxavir
Time frame:
0, 0.5, 2, 4, 10, 24, 72 hours from dose on Day 1 and on Day 4, and Day 7, Day 8
Reported as:
Geometric mean · Hours(h)*nanogram(ng)/milliliter (mL)
Area Under the Concentration to Time Curve From Time 0 to 72 Hours (AUC0-72) of Baloxavir
Hours(h)*nanogram(ng)/milliliter (mL)Baloxavir Marboxil
Day 12820 ± 70.5
Day 43170 ± 53.5
SecondaryMaximum Plasma Concentration (Cmax) of Baloxavir
Time frame:
0, 0.5, 2, 4, 10, 24, 72 hours from dose on Day 1 and on Day 4, and Day 7, Day 8
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) of Baloxavir
ng/mLBaloxavir Marboxil
Day 186.3 ± 64.6
Day 4123 ± 51.7
SecondaryApparent Half-Life (T1/2) of Baloxavir
Time frame:
0, 0.5, 2, 4, 10, 24, 72 hours from dose on Day 1 and on Day 4, and Day 7, Day 8
Reported as:
Geometric mean · Hours (h)
Apparent Half-Life (T1/2) of Baloxavir
Hours (h)Baloxavir Marboxil
Day 118.9 ± NA
Day 423.4 ± 12.8
SecondaryConcentration at 24 Hours (C24) of Baloxavir
Time frame:
0, 0.5, 2, 4, 10, 24, 72 hours from dose on Day 1 and on Day 4, and Day 7, Day 8
Reported as:
Geometric mean · ng/mL
Concentration at 24 Hours (C24) of Baloxavir
ng/mLBaloxavir Marboxil
Day 143.9 ± 74.4
Day 467.1 ± 66.8
Day 7105 ± NA

Adverse events

Collected over Randomization up to Day 35. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Baloxavir Marboxil4/239 (1.7%)29/239 (12.1%)44/239 (18.4%)
Placebo7/124 (5.6%)19/124 (15.3%)27/124 (21.8%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventBaloxavir MarboxilPlacebo
PneumoniaInfections and infestations7/2395/124
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders0/2392/124
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders3/2390/124
Multiple organ dysfunction syndromeGeneral disorders2/2390/124
Pneumonia bacterialInfections and infestations2/2391/124
Acute respiratory failureRespiratory, thoracic and mediastinal disorders2/2391/124
Cardiac failureCardiac disorders1/2391/124
Congestive cardiomyopathyCardiac disorders0/2391/124
ConstipationGastrointestinal disorders0/2391/124
Rectal haemorrhageGastrointestinal disorders0/2391/124
Most frequent other events
Most frequent other events
EventBaloxavir MarboxilPlacebo
ConstipationGastrointestinal disorders10/2396/124
DiarrhoeaGastrointestinal disorders8/2396/124
Hepatic enzyme increasedInvestigations6/2395/124
HypokalaemiaMetabolism and nutrition disorders9/2395/124
HeadacheNervous system disorders9/2392/124
NauseaGastrointestinal disorders7/2394/124
PneumoniaInfections and infestations5/2394/124

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Baloxavir MarboxilPlaceboTotal
Mean58.0 ± 19.861.6 ± 20.359.2 ± 20.0
Sex: Female, Male
Sex: Female, Male(Participants)Baloxavir MarboxilPlaceboTotal
Female11756173
Male12268190
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Baloxavir MarboxilPlaceboTotal
Hispanic or Latino301646
Not Hispanic or Latino203106309
Not Stated415
Unknown213
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Baloxavir MarboxilPlaceboTotal
American Indian or Alaska Native404
Asian392261
Black or African American729
Native Hawaiian or other Pacific Islander101
White18195276
Unknown7512
08

Study locations

170 sites
  • Torrance Memorial Medical Center
    Torrance, California 90505, United States
  • Denver Health Medical Center
    Denver, Colorado 80204, United States
  • Atlanta Institute For Medical Research, Inc; DeKalb Medical Pharmacy
    Decatur, Georgia 30030, United States
  • University of Chicago; Oncology Dept
    Chicago, Illinois 60637, United States
  • NorthShore University HealthSystem
    Evanston, Illinois 60201, United States
  • Barnum Medical Research, Inc.
    Natchitoches, Louisiana 71457, United States
  • Detroit Receiving Hospital
    Detroit, Michigan 48201, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Mercury Street Medical Group
    Butte, Montana 59701, United States
  • Creighton University Medical Center
    Omaha, Nebraska 68131, United States
  • New York-Presbyterian Brooklyn Methodist Hospital; Department of Emergency Medicine
    Brooklyn, New York 11215, United States
  • Temple University Hospital ; Lung Center
    Philadelphia, Pennsylvania 19140, United States
  • Salem Veterans Affairs Medical Center - NAVREF; Pharmacy
    Salem, Virginia 24153, United States
  • Froedtert and The Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Instituto Medico Platense
    La Plata, 1900, Argentina
  • Royal Brisbane & Womens Hospital; Pharmacy Department
    Herston, Queensland 4029, Australia
  • Royal Children's Hospital Melbourne - PIN
    Parkville, Victoria 3052, Australia
  • Hopital Erasme; Chest Medicine, Cardiac & Thoracic Surgery
    Bruxelles, 1070, Belgium
  • Cliniques Universitaires Saint-Luc; Hematology
    Bruxelles, 1200, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Santa Casa de Misericordia; de Belo Horizonte
    Belo Horizonte, MG 30150-221, Brazil
  • Hospital Sao Vicente de Paulo
    Passo Fundo, RS 99010-090, Brazil
  • Centro de Estudos Clinicos do Interior Paulista
    JAU, SP 17201-130, Brazil
  • Multiprofile Hospital For Active Treatment Sveta Ekaterina Dimitrovgrad EOOD; Internal Diseases
    Dimitrovgrad, 6400, Bulgaria
  • Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases - Haskovo EOOD
    Haskovo, 6305, Bulgaria
  • MHAT Stamen Iliev AD; Pharmacy
    Montana, 3400, Bulgaria
  • University Mulitiprofile Hospital for Active Treatment Sveti Georgi EAD; Pharmacy
    Plovdiv, 4002, Bulgaria
  • Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases Dr. D. Gramatikov - Ruse
    Ruse, 7002, Bulgaria
  • Multiprofile Hospital for Active Treatment - Samokov EOOD
    Samokov, 2000, Bulgaria
  • Multiprofile Hospital For Active Treatment Sliven То Military Hospital Sofia; Pharmacy
    Sliven, 8800, Bulgaria
  • Multiprofile Hospital For Active Treatment - Dr. Bratan Shukerov AD; Pharmacy
    Smolyan, 4700, Bulgaria
  • First Multiprofile Hospital for Active Treatment - Sofia EAD
    Sofia, 1142, Bulgaria
  • Fifth Multiprofile Hospital for Active Treatment - Sofia EAD; Pharmacy
    Sofia, 1233, Bulgaria
  • Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia; Pharmacy
    Sofia, 1606, Bulgaria
  • National Multiprofile Transport Hospital Tzar Boris Ill; Clinic of Internal Diseases
    Sofia, 2233, Bulgaria
  • Multiprofile District Hospital for Active Treatment Dr. Stefan Cherkezov AD; Pharmacy
    Veliko Tarnovo, 5000, Bulgaria
  • Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases-Vratsa; Pharmacy
    Vratsa, 3000, Bulgaria
  • Peter Lougheed Centre
    Calgary, Alberta T1Y 6J4, Canada
  • Foothills Medical Centre
    Calgary, Alberta T2N-2T9, Canada
  • Carlson Urology
    Calgary, Alberta T2V 1P9, Canada
  • South Health Campus
    Calgary, Alberta T3M 1M4, Canada
  • University of Alberta Hospital
    Edmonton, Alberta T6G 1Z1, Canada
  • Toronto East General Hospital; Main Pharmacy G Wing Basement
    East York, Ontario M4C 3E7, Canada
  • London Health Sciences Center; Pharmacy Dept.
    London, Ontario N6A 5W9, Canada
  • Institut Universitaire de Cardiologie et de Pneumologie
    Quebec, G1V 4G5, Canada
  • Beijing Youan Hospital, Capital Medical University; Center for Infectious Diseases
    Beijing City, 100069, China
  • Beijing Ditan Hospital Capital Medical University
    Beijing, 100015, China
  • China-Japan Friendship Hospital
    Beijing, 10029, China
  • West China Hospital, Sichuan University
    Chengdu, 610041, China
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, 510120, China
  • The First Affiliated Hospital of College of Medicine, Zhejiang University
    Hangzhou, 310003, China
  • The 1st Affiliated Hospital of Nanchang Unversity
    Nanchang, 330006, China
  • Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital)
    Shanghai, 200025, China
  • Zhongshan Hospital Fudan University
    Shanghai, 200032, China
  • Shanghai Public Health Clinical Center
    Shanghai, 201508, China
  • Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika
    Brno, 625 00, Czechia
  • Nemocnice Kyjov, prispevkova organizace
    Kyjov, 697 33, Czechia
  • East Tallinn Central Hospital
    Tallinn, 10138, Estonia
  • Kuopion Yliopistollinen Sairaala; Silmätaudit
    Kuopio, 70210, Finland
  • Oulun Yliopistollinen Sairaala; Teho-osasto
    Oulu, 90220, Finland
  • Turku University Hospital
    Turku, 20521, Finland
  • Centre Hospitalier Victor Dupouy
    Argenteuil, 95107, France
  • CHRU Dijon Complexe Du Bocage
    Dijon, 21079, France
  • Centre Hospitalier Departemental de Vendee
    La Roche Sur Yon, 85925, France
  • Hôpital Universitaire Dupuytren
    Limoges, 87042, France
  • CHRU Nantes
    Nantes, 44093, France
  • CHU de Nîmes - Hôpital Carémeau
    Nimes, 30029, France
  • Hopital de La Source
    Orleans, 45067, France
  • Groupe Hospitalier Pitie Salpetriere; Service De Pneumologie
    Paris, 75651, France
  • Nouvel Hopital Civil - CHU Strasbourg
    Strasbourg, 67091, France
  • CHRU Bretonneau
    Tours, 37044, France
  • Krankenhaus Donaustauf der LVA Niederbayern Oberpfalz
    Donaustauf, 93093, Germany
  • Universitätsklinikum Carl Gustav Carus an der TU Dresden
    Dresden, 01307, Germany
  • St. Josefskrankenhaus - Freiburg; Klinik fur Pneumologieund Beatmungsmedizin
    Freiburg im Breisgau, 79104, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Uniklinik Koln; Klinik I fur Innere Medizin
    Köln, 50937, Germany
  • Universitatsklinikum Schleswig-Holstein; Klinik fuer Innere Medizin I
    Lubeck, 23538, Germany
  • Klinikum Mannheim GmbH Universitätsklinikum
    Mannheim, 68167, Germany
  • Klinikum der Universität Regensburg
    Regensburg, 93053, Germany
  • Universitatsklinikum Tubingen
    Tübingen, 72076, Germany
  • Princess Margaret Hospital
    Hong Kong, Hong Kong
  • Queen Mary Hospital
    Hong Kong, Hong Kong
  • Prince of Wales Hospital
    Shatin, New Territories, Hong Kong
  • Soroka University Medical Centre
    Beer Sheva, 8410101, Israel
  • Edith Wolfson Medical Center
    Holon, 58100, Israel
  • Galilee Medical Center
    Nahariya, 22100, Israel
  • Chaim Sheba Medical Center; Allergy and Clinical Immunology Unit
    Ramat Gan, 5266202, Israel
  • Rambam Health Corporation; Oncology Institute
    Rambam, 3525408, Israel
  • ZIV Medical Center; Department Of Internal Medicine A
    Safed, 13100, Israel
  • Tel Aviv Sourasky Medical Center; Pharmacy
    Tel Aviv, 6423906, Israel
  • Baruch Padeh Poria Medical Center; Pharmacy
    Tiberias, 15208, Israel
  • Fujita General Hospital
    Dategun Kunimimachi, 969-1793, Japan
  • Shin Komonji Hospital
    Fukuoka, 800-0057, Japan
  • Fukuoka Shin Mizumaki Hospital
    Fukuoka, 807-0051, Japan
  • Fukuoka Wajiro Hospital
    Fukuoka, 811-0213, Japan
  • Rinku General Medical Center
    Izumisano, 598-0048, Japan
  • National Hospital Organization Minami Kyoto Hospital
    Joyo, 610-0113, Japan
  • National Hospital Organization Kanazawa Medical Center
    Kanazawa, 920-8650, Japan
  • Japanese Red Cross Kumamoto Hospital
    Kumamoto-shi, 861-8520, Japan
  • Naha City Hospital
    Naha, 902-8511, Japan

Showing the first 100 of 170 sites across 28 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Stannard HL, Mifsud EJ, Wildum S, Brown SK, Koszalka P, Shishido T, Kojima S, Omoto S, Baba K, Kuhlbusch K, Hurt AC, Barr IG. Assessing the fitness of a dual-antiviral drug resistant human influenza virus in the ferret model. Commun Biol. 2022 Sep 28;5(1):1026. doi: 10.1038/s42003-022-04005-4. PubMed 36171475 ↗
  • Kumar D, Ison MG, Mira JP, Welte T, Hwan Ha J, Hui DS, Zhong N, Saito T, Katugampola L, Collinson N, Williams S, Wildum S, Ackrill A, Clinch B, Lee N. Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial. Lancet Infect Dis. 2022 May;22(5):718-730. doi: 10.1016/S1473-3099(21)00469-2. Epub 2022 Jan 24. PubMed 35085510 ↗
  • Young B, Tan TT, Leo YS. The place for remdesivir in COVID-19 treatment. Lancet Infect Dis. 2021 Jan;21(1):20-21. doi: 10.1016/S1473-3099(20)30911-7. Epub 2020 Nov 26. No abstract available. PubMed 33248473 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Mar 2020, 14 months.

Results were first posted in Nov 2020, 8 months after primary completion.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 14 months is above that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2018
First posted
Sep 25, 2018
StartActual
Jan 8, 2019
Primary completionActual
Mar 16, 2020
CompletionActual
Mar 16, 2020
Results first posted
Nov 30, 2020
Last update
Jan 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03684044
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 25, 2018
Start date
Jan 8, 2019
Primary completion
Mar 16, 2020
Completion
Mar 16, 2020
Results posted
Nov 30, 2020
Last update
Jan 6, 2021

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baloxavir

Start the discussion